Avon Anew Clinical Luminosity Pro Brightening Hand Cream

- 2.6 Oz. : Don't let your hands give away your age. Formulated with injectable-grade L-Aspartic Acid to help inhibit pigment production and fade the look of dark spots.

View the Original article

MassMedia Healthcare Marketing Adds Five Clients

Share: Tweet09
May
2012MassMedia Healthcare Marketing, a full-service public relations, advertising and marketing firm, recently announced that the agency has secured five new clients.

(1888PressRelease) May 09, 2012 - LAS VEGAS - Paula Yakubik, managing partner of MassMedia Healthcare Marketing, a full-service public relations, advertising and marketing firm, recently announced that the agency has secured five new clients including Westfield Nevada Eye and Ear, Matt Smith Physical Therapy, Steljes Cardiology, United Blood Services (UBS) and Diagnostic Center of Medicine.

"MassMedia has a proven track record of helping leading health care companies build their unique brands and reach their customer bases," Yakubik said. "Delivering a coordinated message through advertising and public relations is more important than ever, and our creative team is ready to help our new clients."

Westfield Eye Center and Nevada Eye & Ear recently merged to create Westfield Nevada Eye and Ear. With 19 physicians at six locations in Las Vegas and Pahrump, Westfield Nevada Eye and Ear provides integrated vision services and ear, nose and throat care.

Matt Smith Physical Therapy has served the Las Vegas community since 1984. With 13 locations across the valley, Matt Smith Physical Therapy has grown to become the premier provider of rehabilitative services in Las Vegas. In April, the company began offering balance/vestibular therapy to treat patients with dizziness, vertigo, motion sensitivity and lightheadedness.

Steljes Cardiology is a full service cardiology practice serving the Henderson/Green Valley area serving patients since 2004. Dr. Steljes is one of a handful of cardiologists nationwide who has integrated a sleep medicine program into his practice. He is board certified by the American Board of Internal Medicine in the subspecialty of sleep medicine.

United Blood Services is a nonprofit organization that exists to make a difference in people's lives by inspiring individuals to donate blood. More than 15 million people in 18 states depend on United Blood Services' generous volunteer blood donors to make sure lifesaving blood is available when and where it is needed. There are five United Blood Services locations across Nevada.

The Diagnostic Center of Medicine, in practice since 1977, is one of the largest internal medicine and family medicine groups in Southern Nevada. With three clinics and 17 doctors in Las Vegas and Henderson, Diagnostic Center of Medicine serves as the primary health care provider for over 50 PPO insurers, as well as Medicare, Medicaid and hundreds of private carriers.

About MassMedia
MassMedia Healthcare Marketing is a division of MassMedia Corporate Communications. Founded in 1997, MassMedia is a leading public relations, advertising, government affairs and marketing agency whose knowledge, strategic insights and innovative programs help drive strong corporate reputations.

Healthcare division clients include HealthCare Partners of Nevada, Women's Cancer Center of Nevada, Nevada Spine Clinic, Good Night Pediatrics, Humana, and Nevada Heart and Vascular Center

To learn more about MassMedia Healthcare Marketing, visit www.massmediahealth.com.

###  Other Related Press Releases

by Massmedia Healthcare Marketing

Cincinnati's First Nonprofit Social Media Symposium Announces Speakers by Boot Camp Digital

Doug Briney Cracks Top 10 On Independent Music Network Country Chart by Mts Management

Contact Information

Ryan Tarkowski

Massmedia Healthcare Mar keting

89052

Voice: 702-433-4331

Visit our Site

Press Release Tools

   

View the Original article

Dr.Erik Dalton to Receive Lifetime Achievement

Share: Tweet09
May
2012Renowned author, educator and master therapist Erik Dalton, PhD, was honored with the Lifetime Achievement Award at the 2012 American Massage Conference at the One Concept Gala banquet for his decades of service and innovation in the industry.

(1888PressRelease) May 09, 2012 - Beginning his work as a Certified Rolfer

View the Original article

NIFS to Host a Mass Workout for Facebook Fans

Share: Tweet09
May
2012The National Institute for Fitness and Sport (NIFS) is hosting a mass workout to celebrate reaching 1,000 Likes on Facebook on Saturday, May 12 at 1:00 pm.

Indianapolis, IN (1888PressRelease) May 09, 2012 - Tony Maloney, NIFS Fitness Center Manager, says "this event is a way to say thank you to those that have been following NIFS on Facebook and other social media outlets. It is really the least we can do for the great people of our community to show them how fun fitness can be. We hope to fill the bridge and demonstrate not only to those participating, but the onlookers as well, what NIFS and its staff is all about. Come check us out, you won't regret it!"

The invitation will be posted solely on Facebook. Invitees must wear a red shirt to gain access to the workout. All Facebook fans are welcome whether they are members or guests.

Watch for these red fans meeting on the back patio at NIFS at 1:00 pm and then follow the crew to the Washington Street Bridge. The rain location is the fitness center.

Not a fan yet? There is still time! Find us on Facebook for the latest information.
To find out more about a NIFS fitness center membership, call, e-mail membership (

View the Original article

Tennis Legend Martina Navratilova Will Keynote Living at Your Peak, Vail's Interactive Health Event

Share: Tweet10
May
2012Navratilova joins distinguished panel of health, fitness and longevity experts at exclusive event specifically designed to help people learn how to live longer and better.

(1888PressRelease) May 10, 2012 - Vail, CO - Tennis legend Martina Navratilova will share her unparalleled health and fitness expertise as the keynote speaker at Living at Your Peak (www.livingatyourpeak.org), the Rocky Mountain region's premier interactive wellness experience, the Vail Symposium announced today. The inaugural event, to be held September 13-15, 2012, in Vail, Colo., is the nation's only gathering designed to help health-conscious individuals and influencers discover how to live longer, better and impact the wellbeing of their world.

"You don't need to be an elite athlete to be dedicated to wellness; anyone - at any age - can make a commitment to be fit and healthy," said Navratilova. "As AARP's Health and Fitness Ambassador, I have dedicated my time to helping those of us who are 50

View the Original article

Soybeans soaked in warm water naturally release key cancer-fighting substance

ScienceDaily (May 9, 2012) — Soybeans soaking in warm water could become a new "green" source for production of a cancer-fighting substance now manufactured in a complicated and time-consuming industrial process, scientists are reporting in ACS' Journal of Agricultural and Food Chemistry.

See Also:Health & MedicineCancerOvarian CancerPancreatic CancerPlants & AnimalsSeedsAgriculture and FoodDroughtReferenceIsoflavoneSoy proteinGlutenBean

Hari B. Krishnan and colleagues explain that the substance, Bowman-Birk Protease Inhibitor (BBI), has shown promise for preventing certain forms of cancer in clinical trials. Those human tests resulted from evidence of BBI's beneficial effects, including indications that BBI derived from the large amounts of soybeans in traditional Japanese diets might underpin low cancer mortality rates in Japan. However, the current method of extracting BBI from soybeans is time-consuming and involves harsh chemicals. The scientists set out to see if there might be a greener and more environmentally friendly way of obtaining BBI.

They found that soybean seeds incubated in water at 122 degrees Fahrenheit naturally release large amounts of BBI that can easily be harvested from the water. The protein appeared to be active, with tests showing that it stopped breast cancer cells from dividing in a laboratory dish. "The abundance of BBI in soybean seed exudates by incubating the seeds in warm water provides a simple and alternative method to isolate this low molecular weight protein," the researchers said.

The scientists acknowledge funding from the Agricultural Research Service of the U.S. Department of Agriculture.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

View the Original article

Citywide smoking ban reduced maternal smoking and preterm birth risk

ScienceDaily (May 10, 2012) — A citywide ban on public smoking in Colorado led to significant decreases in maternal smoking and preterm births, providing the first evidence in the U.S. that such interventions can impact maternal and fetal health, according to an article in Journal of Women’s Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

See Also:Health & MedicineSmokingTeen HealthMind & BrainSmoking AddictionBehaviorScience & SocietyPublic HealthSocial IssuesReferencePremature birthBreech birthBirth weightStillbirth

Prenatal exposure to tobacco smoke–whether the mother is a smoker or exposure is from environmental sources– is associated with premature births and low birth weight. The results of a “natural experiment” that compared outcomes in two cities, one with a smoking ban and one without a ban, showed reductions in both maternal smoking and premature births in the city with a smoking ban.

In the article “A Citywide Smoking Ban Reduced Maternal Smoking and Risk for Preterm, Not Low Birth Weight, Births: A Colorado Natural Experiment,” Robert Lee Page II, PharmD, MSPH, Julia Slejko, BA, and Anne Libby, PhD, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences and School of Medicine, Aurora, CO, concluded that a population-level intervention using a smoking ban improved maternal and fetal outcomes.

“Exposure to tobacco smoke is associated with not only death from lung cancer and heart disease but also risks to developing fetuses,” says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women’s Health, Executive Director of the Virginia Commonwealth University Institute for Women’s Health, Richmond, VA, and President of the Academy of Women’s Health. “The promising results of this study suggest that pregnant women and their fetuses represent an important population for further study of health and cost effects of smoke-free ordinances.”

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

View the Original article

FDA report on Gilead's Quad focuses on kidney safety

'modId':'mediatabs_nmid_1_conv_prom','isPreLoad':0,'enableMediaTabEvent':0,'pageSize':12,'numFriends':null,'notificationCount':0,'property':'News','learnMorePath':'/activity-learn-more/','friendbarNotification':'0','friendbarRollup':'0','moduleConf':YAHOO.Media.Facebook.ModuleConf,'friendIdList':

View the Original article

FDA Panel Seems to Back Pill to Help Prevent HIV

HealthDay – 19 hrs ago WEDNESDAY, May 9 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration appears to support the use of the drug Truvada as a means to help prevent HIV infection in people at high risk.

Those individuals might include highly sexually active gay or bisexual men, or the partners of people already infected with HIV, the virus that causes AIDS.

The advisory panel is meeting Thursday to mull whether or not to recommend Truvada as a preventive agent. However, a report released by the FDA this week ahead of the meeting suggests the experts do believe the drug is safe and effective for this use.

There are potential drawbacks to using the medication in this way, however. Truvada -- which combines two HIV-fighting drugs, tenofovir (Viread) and emtricitabine (Emtriva) -- is very expensive and may cause side effects. And although doctors can already prescribe it to people trying to avoid HIV infection, critics say it's too early to officially allow it to be promoted for that use.

On the other hand, those who support marketing the drug as a preventive agent say it can help high-risk people avoid the disease, especially if they don't use condoms or if they want an added layer of protection.

"I don't see it as a panacea, but it's an option, and that's important," said Dr. Kenneth Mayer, an AIDS specialist and medical research director of The Fenway Institute at Fenway Health in Boston. "Some people won't use a condom, but will say, 'if you give me another option, I'll use that.'"

Truvada works to prevent HIV from replicating in the body's cells. Mayer explained that in someone who is not yet infected but is exposed to HIV, the drug may prevent the virus from reproducing even if it's already invaded cells. As a result, he said, "the virus cannot start turning the newly exposed person's body into a 'factory' to produce more HIV particles."

A study published in 2010 in the New England Journal of Medicine found that Truvada cut the risk of HIV infection by almost 44 percent in those at highest risk for contracting the virus, namely sexually active gay and bisexual men. The risk reduction climbed to nearly 73 percent among study participants who took the pill 90 percent of the time, the researchers added.

On Thursday, the FDA advisory panel will meet and come up with advice for federal officials about the possible marketing of the drug as a preventive agent by its manufacturer, Gilead Sciences.

The research suggests that people who use Truvada daily along with condoms would gain an added layer of protection, because condoms aren't 100 percent effective. But one organization, the AIDS Healthcare Foundation, worries that wider use of the drug could lead to more infections by discouraging people from bothering to use condoms.

"Why would you take this medication if you intended to use condoms?" asked the group's president, Michael Weinstein, in an interview with Bloomberg News. He used a sartorial metaphor to elaborate how unlikely that might be: "You've got to be really paranoid about your pants falling down to wear a belt and suspenders."

A. David Paltiel, a professor at Yale School of Medicine, said his research has shown that the use of preventive drug treatments should reduce the risk of infection overall. Still, he said, it's unknown if "people (would) take more chances because they feel protected by a 'chemical condom.'"

Potential markets for Truvada as a preventive drug, Mayer said, include gay men who have sex with more than one man and any committed couple in which one person is HIV-positive, including some heterosexual couples who want to have children.

Mayer, who has conducted research into the drug, said that allowing the marketing will probably lead to an increase in its usage for prevention. But, "this is not a one-time, end-of-the-problem approach like a shot of penicillin to treat an infection like syphilis," he said. "Also, it involves someone perceiving that he or she is at risk, or a provider being comfortable enough to ask about a person's risk. We know that a lot of health providers don't like to talk to their patients about sex."

Truvada can also cause a long list of side effects, including gastrointestinal problems. And it's costly, with prices in the United States tagged at about $26 a day or $10,000 a year. Still, a study released this year found the drug would be cost-effective if used extensively by gay and bisexual men at high risk of becoming infected.

For his part, Paltiel said his research came to the same conclusion: That widespread usage of the drug in high-risk people would be "as cost-effective as other widely accepted public health and medical interventions."

More information

Find out more about HIV/AIDS at the U.S. National Library of Medicine.

View the Original article

FDA Seems to Back Pill to Help Prevent HIV

HealthDay – 13 hrs ago WEDNESDAY, May 9 (HealthDay News) -- U.S. Food and Drug Administration advisers will meet Thursday to decide whether to endorse the use of the drug Truvada as a means to help prevent HIV infection in people at high risk.

Those individuals might include highly sexually active gay or bisexual men, or the partners of people already infected with HIV, the virus that causes AIDS.

A report released by the FDA this week ahead of Thursday's meeting suggests that experts do believe the drug is safe and effective for this use.

There are potential drawbacks to using the medication in this way, however. Truvada -- which combines two HIV-fighting drugs, tenofovir (Viread) and emtricitabine (Emtriva) -- is very expensive and may cause side effects. And although doctors can already prescribe it to people trying to avoid HIV infection, critics say it's too early to officially allow it to be promoted for that use.

On the other hand, those who support marketing the drug as a preventive agent say it can help high-risk people avoid the disease, especially if they don't use condoms or if they want an added layer of protection.

"I don't see it as a panacea, but it's an option, and that's important," said Dr. Kenneth Mayer, an AIDS specialist and medical research director of The Fenway Institute at Fenway Health in Boston. "Some people won't use a condom, but will say, 'if you give me another option, I'll use that.'"

Truvada works to prevent HIV from replicating in the body's cells. Mayer explained that in someone who is not yet infected but is exposed to HIV, the drug may prevent the virus from reproducing even if it's already invaded cells. As a result, he said, "the virus cannot start turning the newly exposed person's body into a 'factory' to produce more HIV particles."

A study published in 2010 in the New England Journal of Medicine found that Truvada cut the risk of HIV infection by almost 44 percent in those at highest risk for contracting the virus, namely sexually active gay and bisexual men. The risk reduction climbed to nearly 73 percent among study participants who took the pill 90 percent of the time, the researchers added.

On Thursday, the FDA advisory panel will meet and come up with advice for federal officials about the possible marketing of the drug as a preventive agent by its manufacturer, Gilead Sciences.

The research suggests that people who use Truvada daily along with condoms would gain an added layer of protection, because condoms aren't 100 percent effective. But one organization, the AIDS Healthcare Foundation, worries that wider use of the drug could lead to more infections by discouraging people from bothering to use condoms.

"Why would you take this medication if you intended to use condoms?" asked the group's president, Michael Weinstein, in an interview with Bloomberg News. He used a sartorial metaphor to elaborate how unlikely that might be: "You've got to be really paranoid about your pants falling down to wear a belt and suspenders."

A. David Paltiel, a professor at Yale School of Medicine, said his research has shown that the use of preventive drug treatments should reduce the risk of infection overall. Still, he said, it's unknown if "people (would) take more chances because they feel protected by a 'chemical condom.'"

Potential markets for Truvada as a preventive drug, Mayer said, include gay men who have sex with more than one man and any committed couple in which one person is HIV-positive, including some heterosexual couples who want to have children.

Mayer, who has conducted research into the drug, said that allowing the marketing will probably lead to an increase in its usage for prevention. But, "this is not a one-time, end-of-the-problem approach like a shot of penicillin to treat an infection like syphilis," he said. "Also, it involves someone perceiving that he or she is at risk, or a provider being comfortable enough to ask about a person's risk. We know that a lot of health providers don't like to talk to their patients about sex."

Truvada can also cause a long list of side effects, including gastrointestinal problems. And it's costly, with prices in the United States tagged at about $26 a day or $10,000 a year. Still, a study released this year found the drug would be cost-effective if used extensively by gay and bisexual men at high risk of becoming infected.

For his part, Paltiel said his research came to the same conclusion: That widespread usage of the drug in high-risk people would be "as cost-effective as other widely accepted public health and medical interventions."

More information

Find out more about HIV/AIDS at the U.S. National Library of Medicine.

View the Original article

Extended Breast-Feeding: Is It More Common than We Think?

Tumblr NewsFeed U.S. Politics World Business Money Tech Health Science Entertainment Opinion Vignette StoryServer 5.0 Tue May 01 09:11:03 2012

View the Original article

Study Says Priobiotics Ward Off Diarrhea After Antibiotics

This story comes from the Yahoo! Contributor Network, where individuals publish their unique perspectives on some of the world’s most popular websites.Do you have a story to tell? Become a Yahoo! contributor

FIRST PERSON

View the Original article